US6228879B1
(en)
*
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
US6429221B1
(en)
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
HU228769B1
(en)
*
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
US5635517B1
(en)
*
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
US7629360B2
(en)
*
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
JP4242651B2
(ja)
*
|
2000-11-30 |
2009-03-25 |
ザ チルドレンズ メディカル センター コーポレイション |
4−アミノ−サリドマイドエナンチオマーの合成法
|
US20030045552A1
(en)
*
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
DE10137163A1
(de)
*
|
2001-07-30 |
2003-02-13 |
Bayer Ag |
Substituierte Isoindole und ihre Verwendung
|
US7153867B2
(en)
*
|
2001-08-06 |
2006-12-26 |
Celgene Corporation |
Use of nitrogen substituted thalidomide analogs for the treatment of macular degenerator
|
AU2003211941A1
(en)
*
|
2002-02-14 |
2003-09-04 |
Ajinomoto Co., Inc. |
Method of analyzing aminofunctional compound and analytical reagent
|
JP2005536189A
(ja)
*
|
2002-04-12 |
2005-12-02 |
セルジーン・コーポレーション |
血管新生のモジュレーターの同定方法、それにより見出された化合物および該化合物を使用する治療方法
|
US7498171B2
(en)
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
WO2003097052A2
(en)
|
2002-05-17 |
2003-11-27 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
|
AU2006202316B2
(en)
*
|
2002-05-17 |
2008-04-10 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
|
US8404716B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
EP1900369A1
(en)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
KR20050057672A
(ko)
*
|
2002-10-24 |
2005-06-16 |
셀진 코포레이션 |
통증의 치료, 변형 및 관리를 위한 면역조절 화합물을포함하는 조성물 및 이의 사용 방법
|
US7563810B2
(en)
*
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
US8034831B2
(en)
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
CN1717177A
(zh)
*
|
2002-11-26 |
2006-01-04 |
人类起源公司 |
细胞治疗剂、细胞治疗单元及其用于治疗的方法
|
JP4613157B2
(ja)
*
|
2003-01-14 |
2011-01-12 |
サイトキネティクス・インコーポレーテッド |
化合物、組成物および方法
|
CN1770976A
(zh)
*
|
2003-02-13 |
2006-05-10 |
人类起源公司 |
利用脐带血治疗患有疾病、紊乱或状况的个体的用途
|
US7320992B2
(en)
*
|
2003-08-25 |
2008-01-22 |
Amgen Inc. |
Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US8952895B2
(en)
|
2011-06-03 |
2015-02-10 |
Apple Inc. |
Motion-based device operations
|
SG133603A1
(en)
*
|
2003-09-17 |
2007-07-30 |
Us Gov Health & Human Serv |
Thalidomide analogs as tnf-alpha modulators
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
US20050100529A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
JP2007510670A
(ja)
*
|
2003-11-06 |
2007-04-26 |
セルジーン・コーポレーション |
サリドマイドを用いた、癌、及び他の疾患を治療、及び管理する方法ならびに組成物
|
CN1913896B
(zh)
*
|
2003-12-02 |
2010-12-01 |
细胞基因公司 |
用于治疗和控制血红蛋白病和贫血病的方法和组合物
|
US20050143344A1
(en)
*
|
2003-12-30 |
2005-06-30 |
Zeldis Jerome B. |
Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
|
CN1956718A
(zh)
*
|
2004-03-22 |
2007-05-02 |
细胞基因公司 |
用于治疗和控制皮肤疾病和病症的含免疫调节化合物的组合物和使用方法
|
US20050222209A1
(en)
*
|
2004-04-01 |
2005-10-06 |
Zeldis Jerome B |
Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
|
MXPA06011798A
(es)
*
|
2004-04-14 |
2007-01-16 |
Celgene Corp |
Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de sindromes mielodisplasticos.
|
BRPI0510110A
(pt)
*
|
2004-04-23 |
2007-09-25 |
Celgene Corp |
método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica
|
JP2005336157A
(ja)
*
|
2004-04-30 |
2005-12-08 |
Arigen Inc |
光学活性サリドマイドおよびその誘導体の製造法
|
CN1984657B
(zh)
*
|
2004-05-05 |
2010-12-15 |
细胞基因公司 |
用于治疗和控制骨髓增生性疾病的包含免疫调节化合物的组合物和使用方法
|
PL1765327T3
(pl)
|
2004-06-17 |
2015-01-30 |
Cytokinetics Inc |
Związki, kompozycje i sposoby
|
US7176222B2
(en)
|
2004-07-27 |
2007-02-13 |
Cytokinetics, Inc. |
Syntheses of ureas
|
WO2006028964A1
(en)
*
|
2004-09-03 |
2006-03-16 |
Celgene Corporation |
Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
|
AU2005302523A1
(en)
*
|
2004-10-28 |
2006-05-11 |
Celgene Corporation |
Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury
|
CA2586950A1
(en)
*
|
2004-11-12 |
2006-05-18 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
|
BRPI0518282A2
(pt)
*
|
2004-11-23 |
2008-11-11 |
Celgene Corp |
uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
EP1901789A2
(en)
*
|
2005-06-30 |
2008-03-26 |
Anthrogenesis Corporation |
Repair of tympanic membrane using placenta derived collagen biofabric
|
PT2380887E
(pt)
*
|
2005-06-30 |
2013-09-18 |
Celgene Corp |
Processos para a preparação de compostos de 4-amino-2-(2,6-dioxopiperidin-3-il)isoindolina-1,3-diona
|
EP1919500A2
(en)
*
|
2005-07-13 |
2008-05-14 |
Anthrogenesis Corporation |
Treatment of leg ulcers using placenta derived collagen biofabric
|
EP1919365A2
(en)
*
|
2005-07-13 |
2008-05-14 |
Anthrogenesis Corporation |
Ocular plug formed from placenta derived collagen biofabric
|
US7538223B2
(en)
|
2005-08-04 |
2009-05-26 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
ES2434946T3
(es)
*
|
2005-08-31 |
2013-12-18 |
Celgene Corporation |
Compuestos de isoindol imida y composiciones que los comprenden y métodos para usarlo
|
EP2301535B1
(en)
|
2005-09-01 |
2014-05-28 |
Celgene Corporation |
Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy
|
US20070066512A1
(en)
*
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
CN1939922B
(zh)
*
|
2005-09-27 |
2010-10-13 |
天津和美生物技术有限公司 |
可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物
|
PE20070771A1
(es)
|
2005-10-13 |
2007-08-11 |
Anthrogenesis Corp |
Inmunomodulacion mediante el uso de celulas madres de la placenta
|
EP1959947A2
(en)
*
|
2005-12-15 |
2008-08-27 |
Cytokinetics, Inc. |
Certain chemical entities, compositions and methods
|
WO2007070683A2
(en)
*
|
2005-12-15 |
2007-06-21 |
Cytokinetics, Inc. |
Certain chemical entities, compositions and methods
|
US20070208000A1
(en)
*
|
2005-12-15 |
2007-09-06 |
Morgan Bradley P |
Certain chemical entities, compositions and methods
|
US7825120B2
(en)
*
|
2005-12-15 |
2010-11-02 |
Cytokinetics, Inc. |
Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
|
EP1959962A2
(en)
*
|
2005-12-16 |
2008-08-27 |
Cytokinetics, Inc. |
Certain chemical entities, compositions, and methods
|
US7989455B2
(en)
*
|
2005-12-19 |
2011-08-02 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
EP2471904B1
(en)
*
|
2005-12-29 |
2018-10-24 |
Celularity, Inc. |
Placental stem cell populations
|
KR20080097190A
(ko)
*
|
2005-12-29 |
2008-11-04 |
안트로제네시스 코포레이션 |
태반 줄기세포의 수집과 보존을 위한 개선된 조성물과 이조성물의 이용 방법
|
WO2007092569A1
(en)
*
|
2006-02-07 |
2007-08-16 |
Battelle Memorial Institute |
Esters of 5 -hydroxymethylfurfural and methods for their preparation
|
WO2007136640A2
(en)
*
|
2006-05-16 |
2007-11-29 |
Celgene Corporation |
Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
TW200806625A
(en)
*
|
2006-05-26 |
2008-02-01 |
Astrazeneca Ab |
Therapeutic compounds
|
WO2008001115A2
(en)
*
|
2006-06-29 |
2008-01-03 |
Astex Therapeutics Limited |
Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
US7993918B2
(en)
|
2006-08-04 |
2011-08-09 |
Anthrogenesis Corporation |
Tumor suppression using placental stem cells
|
US8105634B2
(en)
*
|
2006-08-15 |
2012-01-31 |
Anthrogenesis Corporation |
Umbilical cord biomaterial for medical use
|
WO2008027542A2
(en)
*
|
2006-08-30 |
2008-03-06 |
Celgene Corporation |
5-substituted isoindoline compounds
|
RU2448101C2
(ru)
*
|
2006-08-30 |
2012-04-20 |
Селджин Корпорейшн |
5-замещенные изоиндолиновые соединения
|
US8877780B2
(en)
*
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
JP5567339B2
(ja)
*
|
2006-09-15 |
2014-08-06 |
セルジーン コーポレイション |
N−メチルアミノメチルイソインドール化合物、それを含む組成物、及びその使用方法
|
WO2008042441A1
(en)
*
|
2006-10-03 |
2008-04-10 |
Anthrogenesis Corporation |
Use of umbilical cord biomaterial for ocular surgery
|
US8071135B2
(en)
|
2006-10-04 |
2011-12-06 |
Anthrogenesis Corporation |
Placental tissue compositions
|
EP2664341A3
(en)
*
|
2006-10-06 |
2014-01-08 |
Anthrogenesis Corporation |
Native (telopeptide) placental collagen compositions
|
NZ597779A
(en)
*
|
2007-02-12 |
2013-07-26 |
Anthrogenesis Corp |
Treatment of inflammatory diseases using placental stem cells
|
CN101688177A
(zh)
*
|
2007-02-12 |
2010-03-31 |
人类起源公司 |
来自贴壁胎盘干细胞的肝细胞和软骨细胞;以及cd34+、cd45-胎盘干细胞富集的细胞群
|
AR065810A1
(es)
*
|
2007-03-20 |
2009-07-01 |
Celgene Corp |
Derivados de isoindolina 4'-o-sustituidos,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer y en otros trastornos donde es necesario el control de la angiogenesis o la inhibicion de citoquinas, incluyendo tnf-alfa.
|
US20100172830A1
(en)
*
|
2007-03-29 |
2010-07-08 |
Cellx Inc. |
Extraembryonic Tissue cells and method of use thereof
|
WO2009020590A1
(en)
|
2007-08-07 |
2009-02-12 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
WO2009042177A1
(en)
|
2007-09-26 |
2009-04-02 |
Celgene Corporation |
6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
|
AU2008305516A1
(en)
*
|
2007-09-26 |
2009-04-02 |
Anthrogenesis Corporation |
Angiogenic cells from human placental perfusate
|
SI2203176T1
(sl)
*
|
2007-09-28 |
2015-04-30 |
Anthrogenesis Corporation |
Tumorska supresija z uporabo humanega perfuzata placente in intermediarnih naravnih celic ubijalk, pridobljenih iz humane placente
|
RU2010123002A
(ru)
*
|
2007-11-07 |
2011-12-20 |
Антродженезис Корпорейшн (Us) |
Лечение осложнений преждевременных родов
|
JP2011503062A
(ja)
*
|
2007-11-08 |
2011-01-27 |
セルジーン コーポレイション |
内皮機能障害に伴う障害の治療のための免疫調節化合物の使用
|
WO2009073146A2
(en)
*
|
2007-11-29 |
2009-06-11 |
Celgene Corporation |
Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders
|
CA2710196A1
(en)
*
|
2007-12-20 |
2009-07-09 |
Celgene Corporation |
Use of micro-rna as a biomarker of immunomodulatory drug activity
|
MX2010008220A
(es)
*
|
2008-01-29 |
2010-08-23 |
Celgene Corp |
Metodos que usan compuestos inmunomoduladores para modular nivel de cd59.
|
US20090232796A1
(en)
*
|
2008-02-20 |
2009-09-17 |
Corral Laura G |
Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
|
US8828376B2
(en)
*
|
2008-08-20 |
2014-09-09 |
Anthrogenesis Corporation |
Treatment of stroke using isolated placental cells
|
NZ591292A
(en)
*
|
2008-08-20 |
2012-10-26 |
Anthrogenesis Corp |
Improved cell composition and methods of making the same
|
US8728805B2
(en)
*
|
2008-08-22 |
2014-05-20 |
Anthrogenesis Corporation |
Methods and compositions for treatment of bone defects with placental cell populations
|
PE20140963A1
(es)
|
2008-10-29 |
2014-08-06 |
Celgene Corp |
Compuestos de isoindolina para el tratamiento de cancer
|
RU2015130665A
(ru)
|
2008-11-19 |
2018-12-24 |
Антродженезис Корпорейшн |
Амниотические адгезивные клетки
|
CA2743573C
(en)
*
|
2008-11-21 |
2021-04-27 |
Anthrogenesis Corporation |
Treatment of diseases, disorders or conditions of the lung using placental cells
|
CN102307871A
(zh)
*
|
2008-12-08 |
2012-01-04 |
西特里斯药业公司 |
作为沉默调节蛋白调节剂的异吲哚啉酮和相关的类似物
|
PT2411506T
(pt)
|
2009-03-25 |
2019-03-19 |
Celularity Inc |
Supressão de tumores usando células assassinas naturais intermédias derivadas de placenta humana e compostos imunomoduladores
|
WO2010137547A1
(ja)
|
2009-05-25 |
2010-12-02 |
国立大学法人東京工業大学 |
中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
|
CN101580501B
(zh)
|
2009-06-01 |
2011-03-09 |
南京卡文迪许生物工程技术有限公司 |
3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
|
MX337566B
(es)
|
2010-01-05 |
2016-03-10 |
Celgene Corp |
Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer.
|
WO2011094181A1
(en)
*
|
2010-01-26 |
2011-08-04 |
Anthrogenesis Corporation |
Treatment of bone-related cancers using placental stem cells
|
RS58523B1
(sr)
|
2010-02-11 |
2019-04-30 |
Celgene Corp |
Derivati arilmetoksi izoindolina i kombinacije koje ih obuhvataju i postupci njihove upotrebe
|
CA2794096A1
(en)
|
2010-04-07 |
2011-10-13 |
Celgene Corporation |
Methods for treating respiratory viral infection
|
PT2556145T
(pt)
|
2010-04-07 |
2016-10-25 |
Anthrogenesis Corp |
Angiogénese usando células estaminais placentárias
|
WO2011127113A1
(en)
|
2010-04-08 |
2011-10-13 |
Anthrogenesis Corporation |
Treatment of sarcoidosis using placental stem cells
|
JP5996533B2
(ja)
|
2010-07-13 |
2016-09-21 |
アントフロゲネシス コーポレーション |
ナチュラルキラー細胞を生成させる方法
|
WO2012078492A1
(en)
|
2010-12-06 |
2012-06-14 |
Celgene Corporation |
A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
WO2012092485A1
(en)
|
2010-12-31 |
2012-07-05 |
Anthrogenesis Corporation |
Enhancement of placental stem cell potency using modulatory rna molecules
|
MX2013010360A
(es)
|
2011-03-11 |
2014-04-14 |
Celgene Corp |
Formas solidas sde 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-pi peridin-2,6-diona, y sus composiciones farmaceuticas y usos.
|
EP2699091B1
(en)
|
2011-03-28 |
2017-06-21 |
DeuteRx, LLC |
2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
|
JP2014517915A
(ja)
|
2011-04-18 |
2014-07-24 |
セルジーン コーポレイション |
多発性骨髄腫治療のためのバイオマーカー
|
AU2012249491B2
(en)
|
2011-04-29 |
2016-12-15 |
Celgene Corporation |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
AU2012262273B2
(en)
|
2011-06-01 |
2017-09-14 |
Celularity Inc. |
Treatment of pain using placental stem cells
|
US8927725B2
(en)
|
2011-12-02 |
2015-01-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thio compounds
|
WO2013182662A1
(en)
|
2012-06-06 |
2013-12-12 |
Bionor Immuno As |
Vaccine
|
WO2014004990A2
(en)
|
2012-06-29 |
2014-01-03 |
Celgene Corporation |
Methods for determining drug efficacy using cereblon-associated proteins
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
US9540340B2
(en)
|
2013-01-14 |
2017-01-10 |
Deuterx, Llc |
3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
|
EP2953635A4
(en)
|
2013-02-05 |
2016-10-26 |
Anthrogenesis Corp |
NATURAL KILLER CELLS FROM PLAZENTA
|
EP2968334A4
(en)
|
2013-03-14 |
2016-08-03 |
Deuterx Llc |
3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES
|
US10238690B2
(en)
|
2013-03-15 |
2019-03-26 |
Celgene Corporation |
Modified T lymphocytes comprising an inducible caspase and methods of apoptosis
|
WO2015007337A1
(en)
|
2013-07-19 |
2015-01-22 |
Bionor Immuno As |
Method for the vaccination against hiv
|
CN103421061A
(zh)
*
|
2013-08-14 |
2013-12-04 |
中国药科大学 |
来那度胺衍生物、其制法及其医药用途
|
CN103396397A
(zh)
*
|
2013-08-14 |
2013-11-20 |
中国人民解放军军事医学科学院毒物药物研究所 |
来那度胺衍生物及其作为药物的用途
|
EP3087069B1
(en)
*
|
2013-12-23 |
2019-01-30 |
Norgine B.V. |
Compounds useful as ccr9 modulators
|
MX2016013563A
(es)
*
|
2014-04-14 |
2017-05-09 |
Arvinas Inc |
Moduladores de la proteolisis basados en imida y metodos de uso asociados.
|
JP6640126B2
(ja)
|
2014-06-27 |
2020-02-05 |
セルジーン コーポレイション |
セレブロン及び他のe3ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法
|
US20170165321A1
(en)
|
2014-07-11 |
2017-06-15 |
Bionor Immuno As |
Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids)
|
RS64038B1
(sr)
|
2014-08-22 |
2023-04-28 |
Celgene Corp |
Postupci za lečenje multiplog mijeloma imunomodulatornim jedinjenjima u kombinaciji sa antitelima
|
PT3643709T
(pt)
*
|
2014-10-30 |
2021-12-20 |
Kangpu Biopharmaceuticals Ltd |
Derivado, intermediário, método de preparação, composição farmacêutica de isoindolina e utilização dos mesmos
|
CN107257800B
(zh)
|
2014-12-23 |
2020-06-30 |
达纳-法伯癌症研究所股份有限公司 |
通过双功能分子诱导靶蛋白降解的方法
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
US20170327469A1
(en)
|
2015-01-20 |
2017-11-16 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
KR20230119040A
(ko)
|
2015-01-20 |
2023-08-14 |
아비나스 오퍼레이션스, 인코포레이티드 |
안드로겐 수용체의 표적화된 분해를 위한 화합물 및방법
|
CA2984991A1
(en)
|
2015-05-04 |
2016-11-10 |
Bionor Immuno As |
Dosage regimen for hiv vaccine
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
EP3313818B1
(en)
|
2015-06-26 |
2023-11-08 |
Celgene Corporation |
Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
|
US9809603B1
(en)
|
2015-08-18 |
2017-11-07 |
Deuterx, Llc |
Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
|
WO2017030814A1
(en)
|
2015-08-19 |
2017-02-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
JP6633744B2
(ja)
*
|
2015-09-29 |
2020-01-22 |
カング バイオファーマシューティカルズ リミテッド |
医薬組成物及びその応用
|
WO2017117118A1
(en)
|
2015-12-28 |
2017-07-06 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
|
US11192898B2
(en)
*
|
2016-04-06 |
2021-12-07 |
The Regents Of The University Of Michigan |
MDM2 protein degraders
|
CA3020281A1
(en)
*
|
2016-04-06 |
2017-10-12 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
AU2017250076B2
(en)
*
|
2016-04-12 |
2021-07-22 |
The Regents Of The University Of Michigan |
Bet protein degraders
|
WO2017197055A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
EP3455218A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
WO2017197036A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
JP7009466B2
(ja)
|
2016-10-11 |
2022-02-10 |
アルビナス・オペレーションズ・インコーポレイテッド |
アンドロゲン受容体の標的分解のための化合物および方法
|
MX2019005007A
(es)
|
2016-11-01 |
2019-07-18 |
Arvinas Inc |
Protac dirigidos a la proteína tau y métodos asociados de uso.
|
KR102173464B1
(ko)
|
2016-12-01 |
2020-11-04 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
|
WO2018102786A1
(en)
|
2016-12-03 |
2018-06-07 |
Juno Therapeutics, Inc. |
Methods for modulation of car-t cells
|
BR112019011065A2
(pt)
|
2016-12-03 |
2019-10-01 |
Juno Therapeutics Inc |
métodos para determinação da dosagem de células t car
|
CN110049765B
(zh)
*
|
2016-12-16 |
2022-02-01 |
康朴生物医药技术(上海)有限公司 |
一种组合、其应用及治疗方法
|
KR102564201B1
(ko)
|
2016-12-23 |
2023-08-07 |
아비나스 오퍼레이션스, 인코포레이티드 |
급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
|
EP3559002A4
(en)
|
2016-12-23 |
2021-02-17 |
Arvinas Operations, Inc. |
CHEMERICAL MOLECULES TARGETING EGFR PROTEOLYSIS AND RELATED METHODS OF USE
|
EP3559006A4
(en)
|
2016-12-23 |
2021-03-03 |
Arvinas Operations, Inc. |
COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
EP3573977A4
(en)
|
2017-01-26 |
2020-12-23 |
Arvinas Operations, Inc. |
EESTROGEN RECEPTOR PROTEOLYSIS MODULATORS AND RELATED METHOD OF USE
|
RU2733950C1
(ru)
*
|
2017-02-13 |
2020-10-08 |
Канпу Биофармасьютикалс, Лтд. |
Комбинация для лечения рака предстательной железы, фармацевтическая композиция и способ лечения
|
IL310031A
(en)
|
2017-05-01 |
2024-03-01 |
Juno Therapeutics Inc |
A combination of cellular therapy and an immune modulatory compound
|
US10093647B1
(en)
|
2017-05-26 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
|
AU2018275894A1
(en)
|
2017-06-02 |
2019-12-12 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
CA3067602A1
(en)
|
2017-06-29 |
2019-01-03 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
CN109422751B
(zh)
*
|
2017-09-03 |
2022-04-22 |
上海美志医药科技有限公司 |
一类具有降解酪氨酸蛋白激酶jak3活性的化合物
|
WO2019043208A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
DIHYDROQUINOLINONES
|
CN111315735B
(zh)
|
2017-09-04 |
2024-03-08 |
C4医药公司 |
二氢苯并咪唑酮
|
CN111278815B
(zh)
|
2017-09-04 |
2024-03-08 |
C4医药公司 |
戊二酰亚胺
|
US10093648B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
|
US10093649B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
|
US20200246393A1
(en)
|
2017-09-28 |
2020-08-06 |
Celularity, Inc. |
Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
|
US11623961B2
(en)
|
2017-11-01 |
2023-04-11 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
EP3710002A4
(en)
|
2017-11-16 |
2021-07-07 |
C4 Therapeutics, Inc. |
DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
|
EP3710443A1
(en)
|
2017-11-17 |
2020-09-23 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
JP2021508317A
(ja)
|
2017-12-01 |
2021-03-04 |
ジュノー セラピューティクス インコーポレイテッド |
遺伝子操作された細胞の投与および調節のための方法
|
WO2019118937A1
(en)
|
2017-12-15 |
2019-06-20 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
WO2019146773A1
(ja)
*
|
2018-01-25 |
2019-08-01 |
株式会社フジモト・コーポレーション |
チオフェン誘導体およびその用途
|
JP2021512153A
(ja)
|
2018-01-26 |
2021-05-13 |
イエール ユニバーシティ |
タンパク質分解のイミド系モジュレーターおよび使用方法
|
US11401336B2
(en)
|
2018-02-21 |
2022-08-02 |
Celgene Corporation |
BCMA-binding antibodies and uses thereof
|
KR20210018199A
(ko)
|
2018-03-26 |
2021-02-17 |
씨4 테라퓨틱스, 인코포레이티드 |
이카로스의 분해를 위한 세레블론 결합제
|
CA3095494C
(en)
|
2018-04-04 |
2023-11-07 |
Arvinas Operations, Inc. |
Modulators of proteolysis and associated methods of use
|
WO2019204354A1
(en)
|
2018-04-16 |
2019-10-24 |
C4 Therapeutics, Inc. |
Spirocyclic compounds
|
LT3784663T
(lt)
*
|
2018-04-23 |
2023-10-25 |
Celgene Corporation |
Pakeistieji 4-aminoizoindolin-1,3-diono junginiai ir jų naudojimas limfomos gydymui
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
AU2019294835A1
(en)
|
2018-06-29 |
2020-12-17 |
Dana-Farber Cancer Institute, Inc. |
Ligands to cereblon (CRBN)
|
EP3846800A4
(en)
*
|
2018-09-04 |
2022-08-24 |
C4 Therapeutics, Inc. |
COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1
|
US20220008477A1
(en)
|
2018-11-08 |
2022-01-13 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and t cell modulation
|
WO2020102195A1
(en)
*
|
2018-11-13 |
2020-05-22 |
Biotheryx, Inc. |
Substituted isoindolinones
|
SG11202105084VA
(en)
|
2018-11-16 |
2021-06-29 |
Juno Therapeutics Inc |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
JP2022513685A
(ja)
|
2018-11-30 |
2022-02-09 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法を用いた処置のための方法
|
CN109293631B
(zh)
*
|
2018-11-30 |
2020-05-08 |
常州制药厂有限公司 |
3-氨基-n-(2,6-二氧代-3-哌啶基)-邻苯二甲酰亚胺化合物的制备方法
|
US20220096651A1
(en)
|
2019-01-29 |
2022-03-31 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
US20230248696A1
(en)
*
|
2019-05-03 |
2023-08-10 |
Dynamic Biologics Inc. |
Lenalidomide prodrugs, polymeric conjugates, and formulations thereof, and their uses for the treatment of multiple myeloma
|
AU2020283744A1
(en)
*
|
2019-05-24 |
2021-12-09 |
Biotheryx, Inc. |
Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications
|
EP4041231A1
(en)
*
|
2019-10-09 |
2022-08-17 |
Monte Rosa Therapeutics AG |
Isoindolinone compounds
|
CN114728950A
(zh)
|
2019-11-19 |
2022-07-08 |
百时美施贵宝公司 |
可作为helios蛋白质抑制剂的化合物
|
KR20220119094A
(ko)
|
2019-12-19 |
2022-08-26 |
아비나스 오퍼레이션스, 인코포레이티드 |
안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
|
CA3208313A1
(en)
|
2021-01-13 |
2022-07-21 |
Monte Rosa Therapeutics Ag |
Isoindolinone compounds
|
CN112876414B
(zh)
*
|
2021-01-29 |
2022-09-09 |
河南大学 |
一种基于多胺修饰的萘酰亚胺缀合物、其制备方法及应用
|
WO2022200857A1
(en)
*
|
2021-03-22 |
2022-09-29 |
Monte Rosa Therapeutics Ag |
Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons
|
PE20231941A1
(es)
|
2021-04-06 |
2023-12-05 |
Bristol Myers Squibb Co |
Compuestos de oxoisoindolina sustituidos con piridinilo
|
EP4333836A1
(en)
*
|
2021-05-07 |
2024-03-13 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
CN115504963A
(zh)
*
|
2021-06-22 |
2022-12-23 |
苏州开拓药业股份有限公司 |
一种c-Myc蛋白降解剂
|
WO2023081224A1
(en)
*
|
2021-11-03 |
2023-05-11 |
St. Jude Children's Research Hospital, Inc. |
Substituted n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4- yl)methyl)benzamide analogs as modulators of cereblon protein
|
CN114656374A
(zh)
*
|
2022-02-22 |
2022-06-24 |
营口兴福化工有限公司 |
2,4-二氯-3-氰基-5-氟苯甲酸合成方法
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
KR20240001072A
(ko)
*
|
2022-06-24 |
2024-01-03 |
주식회사 아이비스바이오 |
신규한 포말리도마이드 유도체 및 이의 제조방법
|
US11957759B1
(en)
|
2022-09-07 |
2024-04-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
|